BCL2 and in situ carcinoma: The results showed that CIS administration led to a decrease in mRNA levels of Nrf2, Bcl-2, and HO-1 while increasing the expression of Cas-3, Bax, NFκB, and TNF-α in both liver and kidney tissues (p < 0.0001).